Back to top

Recent Jersey Shore Gatherings That Led to COVID-19 Infections Show How Easily the Virus Can Spread

On Saturday, June 6, Pennsylvania's Bucks County reported 33 new COVID-19 cases. Of those, 11 — or one-third — of these cases were traced back to a person who had spread the virus at recent Jersey Shore beach house gatherings. Another case reported on Friday, June 5th was also traced back to the same person: a New Jersey resident who over the course of two weeks went to several house gatherings at the Jersey Shore.

In a press release, Dr. David Damsker, director of the Bucks County Health Department, reminded residents that it is still important to wear face coverings when attending small gatherings with people not in the same household.

"This is exactly why we can't let our guard down now, even if it feels `safe' to be at the beach," Dr. Damsker said. "One unlucky exposure can lead to a large cascade of cases down the line. We want everyone to enjoy the warmer weather and have fun, but let's keep in mind that COVID is still circulating in the community at baseline levels."

Dr. Damsker said there are likely to be additional infections among family members of the new cases.

Read the full release here.

In our latest HealthDay Now interview, Mabel Jong spoke to Dr. G. Caleb Alexander, a professor at Johns Hopkins who served on the FDA advisory committee that nearly unanimously advised against approving Biogen's new Alzheimer's drug. Dr. Alexander shared his thoughts on the drug's highly uncertain efficacy and discussed whether the FDA's reputation has been permanently damaged by the controversial approval of the drug.

Watch the in-depth discussion above, and see our past HealthDay Nows and other videos on our YouTube channel.

In our latest HealthDay Now interview, Dr. Anton Porsteinsson, a principal investigator for the Biogen aducanumab trial, and Dr. Ken Lin, a primary care physician, discuss the controversial new Alzheimer's drug and whether it will provide any benefit to patients, despite its highly uncertain efficacy and steep cost.

Watch the in-depth discussion above, and see our past HealthDay Nows and other videos on our YouTube channel.

In our latest HealthDay Now interview, Mabel Jong heard from experts with inside knowledge on the FDA's controversial approval of aducanumab.

First up is Dr. G. Caleb Alexander, a professor at Johns Hopkins who served on the FDA advisory committee that nearly unanimously advised against approving Biogen's controversial new Alzheimer's drug. Then, a conversation between Dr. Anton Porsteinsson, a principal investigator for the drug trial, and Dr. Ken Lin, a primary care physician who, like most clinicians surveyed in a new poll, has his concerns and has said he will not prescribe the new drug.

Watch the in-depth discussion above, and see our past HealthDay Nows and other videos on our YouTube channel.

The 2021 conference of the American Diabetes Association (ADA) has concluded. This year, the focus was on the pandemic and the many ways it affected people with diabetes.

In our latest HealthDay Now, Mabel Jong spoke with Dr. Robert Gabbay, the ADA's chief scientific and medical officer. Dr. Gabbay shared important takeaways from the meeting and addressed insulin prices and racial disparities in diabetes care.

Watch the in-depth discussion above, and see our past HealthDay Nows and other videos on our YouTube channel.

Latest